Oncology

Chronic Myeloid Leukemia

Expert Perspectives in Chronic Myeloid Leukemia to Cover Key Topics in Chronic Myeloid Leukemia Treatment

expert perspectives by Gabriela S. Hobbs, MD; Mark J. Levis, MD, PhD; Neil P. Shah, MD, PhD

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Chronic Myeloid Leukemia will feature selected topics in Chronic Myeloid Leukemia that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts:

Gabriela S. Hobbs, MD

Assistant Professor, Medicine
Harvard Medical School
Clinical Director, Leukemia
Massachusetts General Hospital
Boston, MA

Mark J. Levis, MD, PhD

Director, Adult Leukemia Service
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, MD

Neil P. Shah, MD, PhD

Edward S. Ageno Distinguished Professorship in Hematology/Oncology
Professor, Department of Medicine
Director, Molecular Medicine Residency Program
University of California, San Francisco
San Francisco, CA

Community-Selected Topics:

Expert Roundtables

•   Effectiveness of Treatments for Chronic Myeloid Leukemia: Raising the Bar
•   Initial Approach to Newly Diagnosed Patients With Chronic Myeloid Leukemia
•   Chronic Myeloid Leukemia: Current Recommendations for Treatment and Monitoring
•   Risk Stratification and Current Challenges in Chronic Myeloid Leukemia

Clinical Topic Updates

•   Next-Generation Sequencing–Detectable Mutations in Chronic Myeloid Leukemia
•   Cardiovascular Side Effects With Available Tyrosine Kinase Inhibitors
•   Chronic Myeloid Leukemia: Advances in Molecular Monitoring
•   Immune Recovery and Treatment-Free Remission in Chronic Myeloid Leukemia

Patient Care Perspectives

•   COVID-19 and Impacts in Patients With Chronic Myeloid Leukemia
•   Next Steps After Inadequate Response to Established Tyrosine Kinase Inhibitors
•   Recommendations for Second-Generation Tyrosine Kinase Inhibitors as Frontline Therapy
•   Prognostic Scores in Chronic Myeloid Leukemia: Points for Patient Discussion

Profile

Gabriela S. Hobbs, MD

Assistant Professor, Medicine
Harvard Medical School
Clinical Director, Leukemia
Massachusetts General Hospital
Boston, MA

Profile

Mark J. Levis, MD, PhD

Director, Adult Leukemia Service
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, MD